| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2019: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
Based on the advance in recent culture technique, we established patient-derived breast cancer culture and xenograft as disease models that recapitulate clinical breast cancer. Using breast cancer culture and xenograft models, we identified multiple factors including RNA-binding proteins and long noncoding RNA, which contribute to estrogen actions and the progression of endocrine therapy resistance in breast cancer. We demonstrated that these identified factors and their downstream molecules could be clinically applied as molecular targets for alternative diagnostic, therapeutic, and prevention options against advanced breast cancers.
|
